Principal Megan Chacon Explores Changes to Biopharma Patent Landscape During Second Trump Administration 

In an interview with Life Science Leader, Principal Megan Chacon discusses the potential impacts of the incoming Trump administration on drug patents and the biopharmaceutical industry. Chacon highlights key potential changes to anticipate, including the appointment of a new USPTO Director, relaxation of Section 101 requirements, and a renewed focus on strengthening patents. Chacon concludes with advice for biopharma leaders, stressing the importance of patience and communication during this transitional period. 

Excerpt: “Right now, patience and communication are key. Once we start seeing who the new director of the USPTO is, you can start to divine out what other initiatives people are going to want to start doing internally to address that shift. In summary, hold on to your hats. It’s wise for the C-suite to focus on IP, and to have people in various roles within their organizations keeping tabs on these issues as well.” 

Read the full article: What Will The Incoming Trump Administration Mean For Drug Patents?